The strong beat and raised guidance confirm accelerating Growth Portfolio momentum and successful pipeline execution. Watch for upcoming PDUFA catalysts: iberdomide (August 17, 2026) and mezigdomide (May 13, 2027) in multiple myeloma, which could further derisk the long-term growth story. The raised Eliquis guidance (20-25% growth) is a positive surprise given prior generic concerns.
Drugs in focus
BMY drug pipeline →iberdomide
● Neutral Named in this 8-K- Impact
- Phase
- Filed / PDUFA pending (NDA under FDA review; pivotal program completed)
- Time to market
- FDA decision due August 17, 2026 (~2 weeks away); if approved, commercial launch would follow later in 2026.
- Next catalyst
- None dated
What to watchMark August 17, 2026 on the calendar: the FDA target action date for iberdomide in relapsed/refractory multiple myeloma. An approval would give BMY a potential first-in-class oral CELMoD (next-gen successor to its Revlimid/Pomalyst franchise) and is likely a modestly positive headline; a CRL or review extension is the bigger downside risk to watch. Because iberdomide is a small slice of a mega-cap with a rich pipeline (mezigdomide PDUFA already cited for May 2027), treat the decision as a franchise-confidence signal, not a standalone trade.
- ● abatacept 4/10 Approved Named in filing
- ● Opdivo 4/10 Approved Named in filing
- ● Camzyos 3/10 Approved; post-market Phase 3 long-term safety extension completed Named in filing
- ▼ Revlimid 3/10 Approved Named in filing
- ● Zeposia 3/10 Approved (US approval recorded 2020-03-25); no active Phase 2/3 industry-sponsored trials for ozanimod/Zeposia in SecBot Named in filing
- 15 more · All BMY drugs, catalysts & trials →
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 30 $64.86entry
- T+1 · 4mo ago +0.69%α −0.01% · $65.31
- T+5 · 3mo ago −1.09%α −4.72% · $64.15
- T+20 · 3mo ago +3.22%α −0.74% · $66.95
- T+60 · 25d ago −5.21%α −7.68% · $61.48
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Bristol Myers Squibb reported Q2 2026 results significantly above consensus, with non-GAAP EPS of $2.04 beating the $1.60 estimate by 27.7% and revenue of $13.0B exceeding the $11.74B consensus. The company raised its full-year 2026 revenue guidance to $49.0B-$50.0B (from $46.0B-$47.5B) and non-GAAP EPS guidance to $6.75-$7.00 (from $6.05-$6.35), driven by 15% Growth Portfolio revenue growth and broad-based momentum.
Key Financial Metrics
Key Facts
- Q2 2026 total revenues of $12.973B, up 6% YoY (+5% Ex-FX), vs consensus $11.74B
- Non-GAAP EPS of $2.04, up 40% YoY from $1.46, beating consensus of $1.60 by 27.7%
- GAAP EPS of $1.62, up 153% YoY from $0.64
- Growth Portfolio revenues of $7.6B, up 15% YoY (+14% Ex-FX), driven by Opdivo Qvantig, Reblozyl, Camzyos, Breyanzi, and Opdualag
- Legacy Portfolio revenues of $5.4B, down 4% YoY (-5% Ex-FX), with Eliquis up 22% offset by generic erosion on Revlimid (-49%), Pomalyst/Imnovid (-71%), and Sprycel (-27%)
- Full-year 2026 revenue guidance raised to $49.0B-$50.0B (from $46.0B-$47.5B)
- Full-year 2026 non-GAAP EPS guidance raised to $6.75-$7.00 (from $6.05-$6.35)
- Eliquis 2026 WW revenue growth guidance raised to 20%-25% (from 10%-15%)
- Operating expenses guidance increased to ~$16.5B (from $16.3B) for pipeline and launch investments
- Net debt position improved to $31.656B from $34.043B at year-end 2025
- Cash flow from operations was $3.4B in Q2 2026
- ~$5B share repurchase authorization remaining as of June 30, 2026
Financial Impact
Revenue beat consensus by $1.23B (10.5%); non-GAAP EPS beat by $0.44 (27.7%); full-year guidance raised by $3.0B-$2.5B on revenue and $0.70-$0.65 on EPS
Risk Factors
- Legacy Portfolio continues to decline (-4% in Q2) as generic erosion on Revlimid (-49%) and Pomalyst/Imnovid (-71%) accelerates
- Gross margin contracted 120bps YoY to 71.3% (GAAP) due to product mix shift toward Growth Portfolio
- Operating expenses rising to $16.5B guidance reflects increased R&D and launch spending, pressuring near-term margins
- Net debt of $31.7B remains elevated, limiting financial flexibility for large M&A
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000014272-26-000018 |
| Document: bmy-20260730.htm | 0000014272-26-000018 |
| Document: q22026earningspresentati.htm | 0000014272-26-000018 |
| Document: 0000014272-26-000018-index-headers.html | 0000014272-26-000018 |
| Document: 0000014272-26-000018-index.html | 0000014272-26-000018 |
| Document: 0000014272-26-000018.txt | 0000014272-26-000018 |
| 8-K Data (Synthetic) | 0000014272-26-000018 |
Track record
9 reports on BMY
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 6, 202610d ago 144 Neutral 2/10 Entry $62.14 to $62.14 Now $62.93 +1.27% · 0.00% −2.37% vs SPY
- Oct 29, 202618d ago 8-K Neutral 5/10 Entry $61.39 to $62.48 Now $62.93 +2.51% ▲ +1.78% +3.55% vs SPY
- Oct 23, 202624d ago Institutional Cluster Neutral 3/10 Entry $61.48 to $61.61 Now $62.93 +2.36% ▲ +0.21% −0.50% vs SPY
- Oct 5, 20266w ago ANALYST-DOWNGRADE Bearish 4/10 No price data
- Aug 17, 202613w ago Institutional Cluster Bullish 6/10 Entry $64.63 to $66.05 Now $62.93 −2.63% ▲ +2.20% +2.87% vs SPY
- Aug 5, 202614w ago ANALYST-UPGRADE Bullish 4/10 Entry $63.63 to $64.15 Now $62.93 −1.10% ▲ +0.82% +0.98% vs SPY
- Jul 30, 202615w ago 8-K Bullish 7/10 Viewing Entry $64.86 to $65.31 Now $62.93 −2.98% ▲ +0.69% −0.01% vs SPY
- Mar 25, 202633w ago DEFA14A Neutral 3/10 Entry $59.39 to $58.47 Now $62.93 +5.97% ▼ −1.55% +0.13% vs SPY
- Feb 26, 202637w ago Court Ruling Neutral 3/10 Entry $62.37 to $62.34 Now $62.93 +0.90% ▼ −0.05% −0.10% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers